Interventional cardiology in a whole new light

Open menu

News & Events

OPSENS RECEIVES 510(K) CLEARANCE FOR THE OPTOMONITOR II PROVIDING EXTENDED INDICATION

26 September 2016

OPSENS RECEIVES 510(K) CLEARANCE FOR THE OPTOMONITOR II PROVIDING EXTENDED INDICATION Quebec City, Quebec, September 26, 2016 – Opsens Inc. (“Opsens” or the “Company”) (TSXV:OPS) (OTCQX:OPSSF) announces 510(k) clearance from the U.S. Food and Drug Administration (“FDA“) for the OptoMonitor II, a new multimodality monitor combining the ability to measure Fractional Flow Reserve (“FFR”) along…

Read more

OPSENS APPOINTS PAT MACKIN TO ITS BOARD OF DIRECTORS

7 September 2016

Quebec City, Quebec, September 7, 2016 – Opsens Inc. (“Opsens”) (TSXV:OPS) (OTCQX:OPSSF) is pleased to announce the appointment of Mr Pat Mackin as a Director of the Company. “We are delighted to see Pat, a renowned leader in the medical device industry, join us. His expertise as head of leading companies in the cardiovascular space…

Read more